← Eichor
Condition: Waldenstrom Macroglobulinemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Waldenstrom Macroglobulinemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Phase N/A · 7 location(s) · Dana-Farber Cancer Institute · NCT02269592A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemi
Phase N/A · 8 location(s) · BeiGene · NCT05640102Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings
Phase N/A · 1 location(s) · Rigshospitalet, Denmark · NCT07160270A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglob
Phase 4 · 8 location(s) · BeiGene · NCT07169331Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/Phase 2 · 127 location(s) · BeOne Medicines · NCT05006716Spanish Registry of Patients With IgM Monoclonal Gammopathies
Phase N/A · 51 location(s) · Fundación Española de Hematología y Hemoterapía · NCT05093153Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstr
Phase 2/Phase 3 · 25 location(s) · University College, London · NCT04061512Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06550427Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
NA · 1 location(s) · Northwell Health · NCT056432353'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05914662Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT04947618A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Phase 1 · 50 location(s) · Eli Lilly and Company · NCT07101328A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00923507Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglob
NA · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT04893564Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
NA · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT04898647Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Z
Phase 2 · 136 location(s) · National Cancer Institute (NCI) · NCT04840602Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractor
Phase 2 · 17 location(s) · AbbVie · NCT07387471Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06860880
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.